AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16420199 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile of percentage of body fat
Number of subjects: 7523
Study 15685469 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (FNS-IM)
Number of subjects: 16
Study 15685469 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no FNS)
Number of subjects: 16
Study 11387579 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromuscular electric stimulation (perc‐NMES)
Number of subjects: 10
Study 11387579 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous neuromuscular electric stimulation (trans‐NMES)
Number of subjects: 10
Study 9422897 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% xenon
Number of subjects: 54
Study 9422897 — intervention group
Group type: COMPARATOR
Intervention: 60% nitrous oxide with 0.7% sevoflurane
Number of subjects: 54
Study 9422897 — intervention group
Group type: COMPARATOR
Intervention: 60% nitrous oxide with 0.5% isoflurane
Number of subjects: 54
Study 8498150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 14
Study 8498150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3302924 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg every six hours)
Number of subjects: 49
Study 3302924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30001572 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training group (FTG)
Number of subjects: 30
Study 30001572 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study 30001572 — intervention group
Group type: COMPARATOR
Intervention: Both groups (FTG and CON)
Number of subjects: 30
Study 27502847 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based interventions for clinicians
Number of subjects: 9600
Study 27502847 — intervention group
Group type: COMPARATOR
Intervention: Routine practice pattern (Control)
Number of subjects: 9600
Study 23959376 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing agent (5% potassium nitrate, 2% sodium fluoride)
Number of subjects: 30
Study 23959376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22633517 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fluconazole
Number of subjects: 336
Study 22633517 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline colonisation
Number of subjects: 336
Study 22633517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired colonisation
Number of subjects: 336
Study 20038231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 0
Study 20038231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study 18402848 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited free emergency contraceptive pills (ECPs) in advance of need
Number of subjects: 148
Study 18402848 — intervention group
Group type: COMPARATOR
Intervention: Standard access to emergency contraceptive pills (ECPs)
Number of subjects: 148
Study 20635134 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback (n = 6)
Number of subjects: 11
Study 20635134 — intervention group
Group type: COMPARATOR
Intervention: Control 15/min paced breathing (n = 5)
Number of subjects: 11
Study 15806544 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/day) plus antibiotics
Number of subjects: 66
Study 15806544 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics without G-CSF
Number of subjects: 66
Study 11940025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation (TES)
Number of subjects: 0
Study 11940025 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study 11940025 — intervention group
Group type: COMPARATOR
Intervention: Passive placebo
Number of subjects: 0
Study 9604730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg ampul in 100 ml given intravenously in 15 min doses)
Number of subjects: 12
Study 9604730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9604730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol and Placebo
Number of subjects: 12
Study 7798465 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 16
Study 7798465 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 16
Study 3071619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg twice a day
Number of subjects: 19
Study 3071619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg 3 times a day
Number of subjects: 19
Study 11230635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0 mol/L) injected intravenously at doses of 0.1 or 0.3 mmol/kg
Number of subjects: 21
Study 11230635 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0 mol/L) injected intravenously
Number of subjects: 21
Study 29873107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pankowska Equation
Number of subjects: 33
Study 29873107 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate counting
Number of subjects: 33
Study 29873107 — intervention group
Group type: COMPARATOR
Intervention: Food Insulin Index
Number of subjects: 33
Study 27245553 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 15
Study 27245553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27245553 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study 25036731 — intervention group
Group type: EXPERIMENTAL
Intervention: TRP-rich diet (TRP+); 9 BDs, 11 NBDs
Number of subjects: 41
Study 25036731 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CTR); 10 BDs, 11 NBDs
Number of subjects: 41
Study 22086879 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pacing (dual-chamber pacing at 70 bpm)
Number of subjects: 80
Study 22086879 — intervention group
Group type: COMPARATOR
Intervention: Backup pacing (atrial pacing at 30 bpm)
Number of subjects: 80
Study 20563820 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiographs (CR)
Number of subjects: 33
Study 20563820 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 33
Study 19089749 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffeeberry (CB) supplementation at a dose of 800 mg per day for 4 weeks
Number of subjects: 20
Study 19089749 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffeeberry (CB) supplementation
Number of subjects: 20
Study 19089749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) group
Number of subjects: 20
Study 15996846 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy
Number of subjects: 100
Study 15996846 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (group 2a: lesions <5 mm)
Number of subjects: 100
Study 15996846 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (group 2b: lesions 5-9 mm)
Number of subjects: 100
Study 15996846 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (group 2c: lesions >9 mm)
Number of subjects: 100
Study 15996846 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 100
Study 12453951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 30 mg
Number of subjects: 288
Study 12453951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg
Number of subjects: 288
Study 12453951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 288
Study 12453951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 10361754 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education (face-to-face after delivery and during follow-up for 4 months)
Number of subjects: 120
Study 10361754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breastfeeding education)
Number of subjects: 120
Study 7479216 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 30
Study 7479216 — intervention group
Group type: COMPARATOR
Intervention: No erythropoietin treatment
Number of subjects: 30
Study 2320950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzymes
Number of subjects: 37
Study 2320950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 453783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered glycopyrrolate 0.2 mg (Group I)
Number of subjects: 30
Study 453783 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally given analgesic-spasmolytic combination preparation (Group II)
Number of subjects: 30
Study 453783 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication, Group III)
Number of subjects: 30
Study 31658289 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 41430
Study 31658289 — intervention group
Group type: COMPARATOR
Intervention: DPP4 inhibitors
Number of subjects: 41430
Study 29894994 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 25
Study 29894994 — intervention group
Group type: COMPARATOR
Intervention: Histological tissue sample analysis (gold standard)
Number of subjects: 25
Study 27719703 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual group (16 patients) using computer-aided surgical simulation procedure
Number of subjects: 35
Study 27719703 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 patients) using traditional model surgery based on plaster casts
Number of subjects: 35
Study 27719703 — intervention group
Group type: COMPARATOR
Intervention: Comparison between virtual group and control group
Number of subjects: 35
Study 27719703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 25240532 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 0.1 mg/kg
Number of subjects: 231
Study 25240532 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 0.3 mg/kg
Number of subjects: 231
Study 25240532 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 1.5 mg/kg
Number of subjects: 231
Study 25240532 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 10 mg/kg
Number of subjects: 231
Study 25240532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 22773198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid electric vehicle with artificially generated sound (VSP)
Number of subjects: 14
Study 22773198 — intervention group
Group type: COMPARATOR
Intervention: Hybrid electric vehicle without artificially generated sound
Number of subjects: 14
Study 22773198 — intervention group
Group type: COMPARATOR
Intervention: Internal combustion engine vehicle (ICE)
Number of subjects: 14
Study 20880172 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy with narrow-band imaging (ME-NBI)
Number of subjects: 110
Study 20880172 — intervention group
Group type: COMPARATOR
Intervention: Indigocarmine chromoendoscopy (ICC)
Number of subjects: 110
Study 17441321 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 100
Study 17441321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15794387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pirfenidone
Number of subjects: 43
Study 15794387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12485553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to treat (ITT) analysis
Number of subjects: 100
Study 12485553 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded subjects categories
Number of subjects: 100
Study 12485553 — intervention group
Group type: EXPERIMENTAL
Intervention: ITT analysis participant inclusion
Number of subjects: 100
Study 11504982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 31
Study 11504982 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 31
Study 9988364 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (20 mg)
Number of subjects: 12
Study 9988364 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 8156064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonswimming exercises
Number of subjects: 20
Study 8156064 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 30982271 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed group (PCB contamination)
Number of subjects: 60
Study 30982271 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no PCB exposure)
Number of subjects: 60
Study 30982271 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed group
Number of subjects: 60
Study 30982271 — intervention group
Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 60
Study 29153975 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy (EAT) withdrawn after 72 hours of apyrexia plus clinical recovery.
Number of subjects: 157
Study 29153975 — intervention group
Group type: COMPARATOR
Intervention: Empirical antimicrobial therapy (EAT) withdrawn when neutrophil count was 0.5 x 10^9 cells per L or higher.
Number of subjects: 157
Study 29153975 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EAT) adverse events reported: 341
Number of subjects: 157
Study 29153975 — intervention group
Group type: COMPARATOR
Intervention: Control group (EAT) adverse events reported: 295
Number of subjects: 157
Study 29153975 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe adverse events in experimental group: 18
Number of subjects: 157
Study 29153975 — intervention group
Group type: COMPARATOR
Intervention: Severe adverse events in control group: 38
Number of subjects: 157
Study 25393038 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival Bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 46
Study 25393038 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Control group)
Number of subjects: 46
Study 23689809 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (15 to 20 mg/kg per day for 3 months)
Number of subjects: 50
Study 23689809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21339653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide ‐ Isoflurane anesthesia (Nitrous oxide‐based group)
Number of subjects: 116
Study 21339653 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia (Nitrous oxide‐free group)
Number of subjects: 116
Study 19229497 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT SL-5 lotion (containing cell-free culture supernatant of E. faecalis SL-5)
Number of subjects: 0
Study 19229497 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 0
Study 16536664 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 90
Study 16536664 — intervention group
Group type: COMPARATOR
Intervention: Self-help manual only (SH)
Number of subjects: 90
Study 14642690 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐BNP group (GP received the N‐BNP result)
Number of subjects: 305
Study 14642690 — intervention group
Group type: COMPARATOR
Intervention: Control group (GP did not receive the N‐BNP result)
Number of subjects: 305
Study 11140073 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based support and educational group for 5 months
Number of subjects: 30
Study 11140073 — intervention group
Group type: COMPARATOR
Intervention: Usual modes of support and communication (Control)
Number of subjects: 30
Study 11327445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fozivudine tidoxil 1200 mg/day
Number of subjects: 0
Study 11327445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fozivudine tidoxil 800 mg/day
Number of subjects: 0
Study 11327445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fozivudine tidoxil 400 mg/day
Number of subjects: 0
Study 11327445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8255556 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine administration (oral and intramuscular)
Number of subjects: 0
Study 3518724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (200-300 mg single oral dose)
Number of subjects: 8
Study 3518724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d. for 15 days)
Number of subjects: 8
Study 3518724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg t.i.d. long-term treatment for 6 months)
Number of subjects: 8
Study 3518724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30742244 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α treatment (group B)
Number of subjects: 133
Study 30742244 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) and sulfasalazine (SSZ) (group A)
Number of subjects: 133
Study 29880356 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 μg/d)
Number of subjects: 124
Study 29880356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 26762128 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adaptive storytelling method intervention
Number of subjects: 100
Study 26762128 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 23937217 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration mapping from perceptual units to action units during throwing and extended reaching
Number of subjects: 0
Study 23937217 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-specific approach to calibration
Number of subjects: 0
Study 23937217 — intervention group
Group type: EXPERIMENTAL
Intervention: General purpose perception approach
Number of subjects: 0
Study 22554931 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (2 mg folic acid, 25 mg vitamin B(6), and 500 μg vitamin B(12))
Number of subjects: 8164
Study 20851549 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min infusion of imipenem/cilastatin
Number of subjects: 18
Study 20851549 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h infusion of imipenem/cilastatin
Number of subjects: 18
Study 20851549 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min infusion of meropenem
Number of subjects: 18
Study 20851549 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h infusion of meropenem
Number of subjects: 18
Study 17625106 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 164
Study 17625106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 16304444 — intervention group
Group type: COMPARATOR
Intervention: dilute formocresol
Number of subjects: 107
Study 16304444 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 107
Study 16304444 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium hydroxide
Number of subjects: 107
Study 16304444 — intervention group
Group type: EXPERIMENTAL
Intervention: ferric sulfate
Number of subjects: 107
Study 12887823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 96
Study 12887823 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 96
Study 12887823 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ramipril and Losartan
Number of subjects: 96
Study 10457535 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 0
Study 10457535 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 0
Study 10457535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7555614 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg t.i.d.)
Number of subjects: 0
Study 7555614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1741645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic resection
Number of subjects: 21
Study 1741645 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative peritoneal lavage
Number of subjects: 21
Study 1741645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 6753500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 139
Study 6753500 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 139
Study 6753500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 6740281 — intervention group
Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine (DEV), administered according to the prescribed schedule (14 initial inoculations and 3 boosters)
Number of subjects: 0
Study 6740281 — intervention group
Group type: EXPERIMENTAL
Intervention: Duck embryo rabies vaccine (DEV)
Number of subjects: 0
Study 31560051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin (OVP) 125 mg once daily for 5 days post-systemic antibiotics
Number of subjects: 100
Study 31560051 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 100
Study 31560051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin (OVP)
Number of subjects: 100
Study 30465358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide alone
Number of subjects: 60
Study 30465358 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide in combination with 2% chlorhexidine gel
Number of subjects: 60
Study 30465358 — intervention group
Group type: COMPARATOR
Intervention: Control group (Calcium hydroxide alone)
Number of subjects: 60
Study 26698636 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 7072
Study 26698636 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 7072
Study 24794368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (4 mg/kg/d for 2 weeks) and oral prednisolone (2 mg/kg/d for 2 weeks) followed by a tapering protocol for 9 weeks
Number of subjects: 140
Study 24794368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 24794368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone and oral prednisolone
Number of subjects: 140